Regulatory Milestone for Oral Obesity Drugs Boosts Viking Therapeutics Shares
Published on 12/23/2025 at 22:43 | Redaktion boerse-global.de
Shares of Viking Therapeutics gained approximately 2.9% to $36.42 following a pivotal regulatory decision that is reshaping the market for weight-loss medications. The catalyst was the U.S. Food and Drug Administration (FDA) granting its first-ever approval for an oral version of Novo Nordisk’s Wegovy. This development is viewed less as a direct company announcement from Viking and more as a significant positive signal for the entire oral GLP-1 therapy sector.
The FDA’s approval of oral Wegovy (semaglutid 25 mg) for chronic weight management represents a long-anticipated validation for the industry. It formally confirms that tablet-based GLP-1 treatments are both commercially viable and meet regulatory standards, setting a clear precedent Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
